Posts by: Patricia Inacio PhD

News

After failing to significantly extend survival in a confirmatory Phase 3 trial, Keytruda (pembrolizumab) will no longer be available in the U.S. for people with previously treated metastatic small cell lung ... Read more

February 26, 2021February 26, 2021

Trial Will Test AFM24-Tecentriq Combo for EGFR-positive Advanced Cancers

News

Affimed will team up with Roche to conduct a Phase 1/2a clinical trial investigating its innate cell engager AFM24 — a form of immunotherapy — in combination with Tecentriq (atezolizumab) ... Read more

February 24, 2021February 24, 2021

Tebentafusp Named FDA Breakthrough Therapy for Advanced Eye Cancer

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Immunocore‘s tebentafusp (IMCgp100) for HLA-A2 positive, inoperable, or advanced uveal melanoma — a common and difficult-to-treat form of ... Read more

February 5, 2021February 5, 2021

Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumors

News

Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to develop a new “off-the-shelf” immunotherapy for solid tumors. The immunotherapy is based on “natural killer” ... Read more

January 27, 2021January 27, 2021

Bavencio Approved in EU as First-line Maintenance Therapy for Bladder Cancer

News

The European Commission (EC) has approved Bavencio (avelumab) as a first-line maintenance treatment for adults with advanced urothelial carcinoma, the most common form of bladder cancer, whose disease did not progress after ... Read more

January 25, 2021January 25, 2021

Retifanlimab Under FDA Priority Review for Advanced Anal Canal Cancer

News

Retifanlimab is under review in the U.S. as a treatment for advanced squamous cell carcinoma of the anal canal (SCAC), a rare cancer of the digestive system, in adults who ... Read more

December 7, 2020December 7, 2020

FDA Approves Less Frequent Treatment Regimen for Imfinzi in NSCLC, Bladder Cancer

News

The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for the treatment of certain non-small cell lung cancer (NSCLC) and bladder cancer patients. Granted under priority review, ... Read more

November 9, 2020November 9, 2020

Opdivo-Yervoy-Chemo Combo Approved in EU for Advanced NSCLC

News

The European Commission has approved a combination of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) ... Read more

October 26, 2020October 27, 2020

Opdivo-Cabometyx Granted FDA Priority Review for Newly Diagnosed Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has agreed to review applications requesting the approval of Opdivo (nivolumab) in combination with Cabometyx (cabozantinib) for people with advanced renal cell cancer, the most common type of ... Read more

October 21, 2020October 21, 2020

Committee Recommends EU Approval of Opdivo to Treat Advanced Esophageal Cancer

News

A committee of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who ... Read more